RCC Laboratories, a leading contract research organisation providing preclinical and safety toxicology and chemical testing globally and ViruSure announced their partnership to market the services of ViruSure in India. Through this partnership RCC will act as a sole agent for promoting ViruSure services in India.
ViruSure offers services in the areas of virus and prion safety testing for biopharmaceutical products, cell banking and cell bank characterisation services and in vivo biosafety studies (adventitious agent testing, tumorigenicity testing, oncogenicity testing), which are highly valuable to pharma and biotech companies specialising on biological products (e.g. recombinant proteins, vaccines, human and animal derived biological products, cell based therapies).
“We are happy to partner with such a renowned company as RCC, who shares the same philosophy of quality and customer service that has made ViruSure successful. We look forward to offer our experience to assist Indian biopharmaceutical companies in reaching their goals for pathogen safety testing,” stated Andy Bailey, CEO and co-founder of ViruSure.
The partnership is a natural fit, since both RCC and ViruSure will help Indian companies elevate their quality standards through their combined service offerings.
RCC offers OECD toxicology services to various companies in India and globally, with quality, and transparency as the main focus. The RCC team prides itself in adhering to strict timelines and fast responses to queries. With an experienced team of toxicologists, RCC is a leader in pre-clinical toxicology services in Asia. The team at RCC works under the philosophy that “the products we test are the products you buy” hence a strict and robust quality management system is the secret to its success.
EP News Bureau